Small molecules, like drugs, hormones, vitamins, and pesticides, are ubiquitous in our environment and form key analytes that are routinely monitored in healthcare and drug development. Our Optimer platform…

04/02/2020 Biotechnology companies Aptamer Group and Valitacell Ltd have joined forces to develop a next-generation screening platform for drug development. Aptamer Group will be working alongside Valitacell…

08/01/2019 Aptamer Group today announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney. The two-year agreement will give AstraZeneca…